Norman Markowitz

4.3k total citations · 1 hit paper
65 papers, 2.8k citations indexed

About

Norman Markowitz is a scholar working on Infectious Diseases, Virology and Epidemiology. According to data from OpenAlex, Norman Markowitz has authored 65 papers receiving a total of 2.8k indexed citations (citations by other indexed papers that have themselves been cited), including 38 papers in Infectious Diseases, 22 papers in Virology and 22 papers in Epidemiology. Recurrent topics in Norman Markowitz's work include HIV Research and Treatment (22 papers), HIV/AIDS Research and Interventions (20 papers) and HIV/AIDS drug development and treatment (15 papers). Norman Markowitz is often cited by papers focused on HIV Research and Treatment (22 papers), HIV/AIDS Research and Interventions (20 papers) and HIV/AIDS drug development and treatment (15 papers). Norman Markowitz collaborates with scholars based in United States, Australia and Denmark. Norman Markowitz's co-authors include Louis D. Saravolatz, Edward Quinn, Paul A. Kvale, Jeanne M. Wallace, Jeffrey Glassroth, Philip C. Hopewell, Mark J. Rosen, Bonita T. Mangura, Timothy C. Wilcosky and Donald C. Çox and has published in prestigious journals such as New England Journal of Medicine, Annals of Internal Medicine and PLoS ONE.

In The Last Decade

Norman Markowitz

63 papers receiving 2.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Bacterial Pneumonia in Persons Infected with the Human Immunodeficiency Virus

1995 472 citations Jeffrey Glassroth, Jeanne M. Wallace et al. New England Journal of Medicine profile →

Peers

Countries citing papers authored by Norman Markowitz

Since Specialization

Citations

This map shows the geographic impact of Norman Markowitz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Norman Markowitz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Norman Markowitz more than expected).

Fields of papers citing papers by Norman Markowitz

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Norman Markowitz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Norman Markowitz. The network helps show where Norman Markowitz may publish in the future.

Co-authorship network of co-authors of Norman Markowitz

This figure shows the co-authorship network connecting the top 25 collaborators of Norman Markowitz. A scholar is included among the top collaborators of Norman Markowitz based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Norman Markowitz. Norman Markowitz is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Longitudinal Patient-Reported Outcomes in Older Adults With Aggressive Lymphomas Receiving Chemoimmunotherapy 2025 ·Journal of the National Comprehensive Cancer Network ·P. Connor Johnson, Jeremy S. Abramson, Ann S. LaCasce, Philippe Armand, Jeffrey A. Barnes, Reid W. Merryman, Jacob D. Soumerai, Ephraim P. Hochberg, Ronald W. Takvorian, Caron A. Jacobson, Jennifer L. Crombie, David C. Fisher, Joel Schwartz, Robb S. Friedman, (unknown), (unknown), (unknown), Norman Markowitz, Oreofe O. Odejide, Areej El‐Jawahri	1
2	1615. Efficacy of Long-Acting Cabotegravir and Rilpivirine in a Diverse Group of Patients in a Real-World Setting 2023 ·Open Forum Infectious Diseases ·Nicholas Yared, Smitha Gudipati, Shannon R. Payne, (unknown), (unknown), (unknown), Norman Markowitz, Indira Brar	4
3	Increase in False-Positive Fourth-Generation Human Immunodeficiency Virus Tests in Patients With Coronavirus Disease 2019 2023 ·Clinical Infectious Diseases ·Smitha Gudipati, Anita Shallal, Edward L. Peterson, Bernard Cook, Norman Markowitz	7
4	Seroprevalence of antibodies against sars-cov-2 among people living with hiv (PLWH) 2021 ·Smitha Gudipati, (unknown), (unknown), (unknown), Nicholas Yared, Indira Brar, (unknown), Norman Markowitz	1
5	Descriptive Analysis of Patients Living With HIV Affected by COVID-19 2020 ·JAIDS Journal of Acquired Immune Deficiency Syndromes ·Smitha Gudipati, Indira Brar, (unknown), John E. McKinnon, Nicholas Yared, Norman Markowitz	25
6	NMO-IgG positive relapsing longitudinally extensive transverse myelitis (LETM) in a seropositive HIV patient 2013 ·Clinical Neurology and Neurosurgery ·(unknown), Mirela Cerghet, (unknown), Norman Markowitz	9
7	Late presentation and transmitted drug resistance mutations in new HIV-1 diagnoses in Detroit 2011 ·International Journal of Infectious Diseases ·Moisés A. Huamán, Javier Aguilar, Dwayne Baxa, (unknown), Indira Brar, Norman Markowitz	11
8	Epidemiologic characteristics and transmitted drug resistance mutation patterns among newly diagnosed HIV infected individuals in a large tertiary care hospital in Detroit 2010 ·International Journal of Infectious Diseases ·Moisés A. Huamán, Juan Javier Aguilar, Norman Markowitz, Dwayne Baxa, (unknown), Indira Brar	1
9	Patient characteristics and costs associated with dyslipidaemia and related conditions in HIV‐infected patients: a retrospective cohort study 2005 ·HIV Medicine ·Adrian Richter, Manel Pladevall, R Manjunath, (unknown), Hugo Xi, (unknown), Indira Brar, Norman Markowitz, (unknown), William Irish	24
10	Nadir CD4+ T Cell Count Predicts Response to Subcutaneous Recombinant Interleukin-2 2003 ·Clinical Infectious Diseases ·Norman Markowitz, Judith D. Bebchuk, Donald I. Abrams	17
11	Randomized, Open-Label Study of the Impact of Two Doses of Subcutaneous Recombinant Interleukin-2 on Viral Burden in Patients With HIV-1 Infection and CD4+ Cell Counts of ≥300/mm3: CPCRA 059 2002 ·JAIDS Journal of Acquired Immune Deficiency Syndromes ·Donald I. Abrams, Judith D. Bebchuk, Eileen Denning, Richard T. Davey, Lawrence K. Fox, H. Clifford Lane, (unknown), (unknown), (unknown), Norman Markowitz	11
12	Optimistic explanatory style and dispositional optimism in HIV-infected men 2001 ·Journal of Psychosomatic Research ·(unknown), Mark A. Lumley, Norman Markowitz, (unknown)	51
13	Overall and cause-specific mortality in a cohort of homo-/bisexual men, injecting drug users, and female partners of HIV-infected men 1996 ·AIDS ·W. Kenneth Poole, W. J. Fulkerson, Yu Lou, Paul A. Kvale, P C Hopewell, (unknown), Jeffrey Glassroth, Mark J. Rosen, Bonita T. Mangura, Jeanne M. Wallace, Norman Markowitz	13
14	Cryptococcal Empyema: Case Report and Review 1995 ·Clinical Infectious Diseases ·Victor E. Mulanovich, William E. Dismukes, Norman Markowitz	13
15	A Comparative Trial of Didanosine or Zalcitabine after Treatment with Zidovudine in Patients with Human Immunodeficiency Virus Infection 1994 ·New England Journal of Medicine ·Donald I. Abrams, Anne I. Goldman, Cynthia A. Launer, Joyce A. Korvick, James D. Neaton, Lawrence R. Crane, (unknown), Steven Wakefield, K Muth, (unknown), David L. Cohn, (unknown), Roberta Luskin‐Hawk, Norman Markowitz, James Sampson, Melanie Thompson, Lawrence Deyton	150
16	Routine Analysis of Induced Sputum Is Not an Effective Strategy for Screening Persons Infected with Human Immunodeficiency Virus for Mycobacterium tuberculosis or Pneumocystis carinii 1994 ·Clinical Infectious Diseases ·Paul A. Kvale, Nellie I. Hansen, Norman Markowitz, (unknown), (unknown), (unknown), Jeffrey Glassroth, (unknown), Jeanne M. Wallace, John Stansell, Philip C. Hopewell, (unknown)	7
17	Quantitation of Unintegrated HIV-1 DNA in Asymptomatic Patients in the Presence or Absence of Antiretroviral Therapy 1993 ·AIDS Research and Human Retroviruses ·Charlene E. Bush, Richard Donovan, (unknown), (unknown), Norman Markowitz, Louis D. Saravolatz	14
18	Trimethoprim-Sulfamethoxazole Compared with Vancomycin for the Treatment of Staphylococcus aureus Infection 1992 ·Annals of Internal Medicine ·Norman Markowitz, Edward Quinn, Louis D. Saravolatz	277
19	Safety, Pharmacokinetics, and Functional Activity of Human Anti-Pseudomonas aeruginosa Monoclonal Antibodies in Septic and Nonseptic Patients 1991 ·The Journal of Infectious Diseases ·Louis D. Saravolatz, Norman Markowitz, Michael Collins, Derek Bogdanoff, James E. Pennington	20
20	Infected False Aneurysms of the Femoral Artery in Intravenous Drug Addicts 1989 ·Clinical Infectious Diseases ·(unknown), (unknown), Norman Markowitz, Louis D. Saravolatz	22

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact